The article “Processing and extraction methods of medicinal cannabis: a narrative review” by Russo et al. (2023) reviews the various processing and extraction methods used to produce medicinal cannabis products. The authors discuss the advantages and disadvantages of each method, and the impact of each method on the quality and safety of the final product.

Processing methods

The processing of medicinal cannabis begins with the harvesting and drying of the plant material. The dried plant material can then be ground into a powder or milled into smaller pieces. This process helps to increase the surface area of the plant material, which makes it easier to extract the cannabinoids and other compounds of interest.

Once the plant material has been processed, it can be extracted using a variety of methods. The most common extraction methods include:

• Solvent extraction: This method uses a solvent, such as ethanol, butane, or hexane, to dissolve the cannabinoids and other compounds of interest. The solvent is then removed using evaporation or distillation, leaving behind a concentrated extract.
• Supercritical fluid extraction: This method uses supercritical carbon dioxide to extract the cannabinoids and other compounds of interest. Supercritical carbon dioxide is a fluid that has the properties of both a gas and a liquid. It is very effective at extracting cannabinoids and other compounds from plant material.
• Mechanical extraction: This method uses mechanical force, such as pressing or sieving, to extract the cannabinoids and other compounds of interest. Mechanical extraction is a gentle method that preserves the terpenes and other volatile compounds in the plant material.

Advantages and disadvantages of different extraction methods

Solvent extraction is the most common extraction method used to produce medicinal cannabis products. It is a relatively simple and inexpensive method, and it can be used to extract a wide range of compounds from plant material. However, solvent extraction can also produce extracts that contain residual solvents, which can be harmful to human health.

Supercritical fluid extraction is a more expensive extraction method than solvent extraction, but it is also a more efficient and environmentally friendly method. Supercritical fluid extraction produces extracts that are free of residual solvents, and it preserves the terpenes and other volatile compounds in the plant material.

Mechanical extraction is the most gentle extraction method, and it produces extracts that are free of residual solvents and other contaminants. However, mechanical extraction is also the least efficient extraction method, and it cannot be used to extract all of the compounds of interest from plant material.

Impact of processing and extraction methods on the quality and safety of medicinal cannabis products

The quality and safety of medicinal cannabis products is dependent on a number of factors, including the processing and extraction methods used. It is important to use high-quality processing and extraction methods to produce safe and effective medicinal cannabis products.

Solvent extraction can produce extracts that contain residual solvents, which can be harmful to human health. It is important to use a high-quality solvent extraction method that removes all of the residual solvents from the final product.

Supercritical fluid extraction produces extracts that are free of residual solvents and other contaminants. However, it is important to use a high-quality supercritical fluid extraction method that preserves the terpenes and other volatile compounds in the plant material.

Mechanical extraction produces extracts that are free of residual solvents and other contaminants. However, it is important to use a high-quality mechanical extraction method that is efficient and can extract all of the compounds of interest from the plant material.

Conclusion

The processing and extraction methods used to produce medicinal cannabis products have a significant impact on the quality and safety of the final product. It is important to choose high-quality processing and extraction methods that produce safe and effective medicinal cannabis products.

The article “Processing and extraction methods of medicinal cannabis: a narrative review” by Russo et al. (2023) provides a comprehensive overview of the various processing and extraction methods used to produce medicinal cannabis products. The authors discuss the advantages and disadvantages of each method, and the impact of each method on the quality and safety of the final product ¹.

The processing of medicinal cannabis begins with the harvesting and drying of the plant material. The dried plant material can then be ground into a powder or milled into smaller pieces, which increases the surface area of the plant material, making it easier to extract the cannabinoids and other compounds of interest ¹.

The article describes three common extraction methods: solvent extraction, supercritical fluid extraction, and mechanical extraction. Solvent extraction is the most common method used to produce medicinal cannabis products. It uses a solvent such as ethanol, butane, or hexane to dissolve the cannabinoids and other compounds of interest. The solvent is then removed using evaporation or distillation, leaving behind a concentrated extract ¹.

Supercritical fluid extraction uses supercritical carbon dioxide to extract cannabinoids and other compounds from plant material. Supercritical carbon dioxide is a fluid that has the properties of both a gas and a liquid, making it very effective at extracting cannabinoids and other compounds from plant material ¹.

Mechanical extraction uses mechanical force such as pressing or sieving to extract cannabinoids and other compounds from plant material. This method is gentle and preserves terpenes and other volatile compounds in the plant material ¹.

Each method has its own advantages and disadvantages. Solvent extraction is relatively simple and inexpensive, but it can leave behind trace amounts of solvents in the final product. Supercritical fluid extraction is more expensive but produces a cleaner product with fewer impurities. Mechanical extraction is gentle but less efficient than solvent or supercritical fluid extraction ¹.

¹: Russo, E.B., Marcu, J., & Upton, R. (2023). Processing and extraction methods of medicinal cannabis: a narrative review. Journal of Cannabis Research, 3(32). https://doi.org/10.1186/s42238-021-00087-9

Learn more:

1. jcannabisresearch.biomedcentral.com2. jcyounger.com3. deltaseparations.com4. europepmc.org5. jcannabisresearch.biomedcentral.com

Delta-8 THC, recognized widely within the realm of cannabinoids, is a psychoactive substance that shares resemblances to another cannabinoid, the delta-9 THC, which is known to be the primary psychoactive compound in cannabis. The scientific research reports the interesting fact that delta-8 THC, despite its similarities, only possesses about half of the potency delta-9 THC has, which makes its induced high less intense, certainly more gentle, leading to a more serene, calming, and soothing experience for the user. Reporting on its potential therapeutic benefits, delta-8 THC has been shown to provide relief from a diverse range of health issues. These include the alleviation of pain, a common symptom of many chronic conditions. Further, it can provide relief for those suffering from persistent nausea, an often debilitating symptom that can stem from various causes. Moreover, the cannabinoid is found to be highly effective in reducing inflammation, a key factor in numerous diseases like arthritis, heart disease, and even cancer. Delta-8 THC also addresses loss of appetite, often associated with illnesses that require rigorous treatments like chemotherapy. This can be of great help in maintaining the patient’s nutritional status and overall health. Additionally, it’s been reported to have possible antidepressant effects, providing relief from depressive symptoms, thereby enhancing the quality of life for those affected. Furthermore, delta-8 THC may also have a positive impact on cancer patients undergoing treatment. It has been suggested that the compound may stimulate appetite, countering the common chemotherapy side effect of appetite loss. This can be a major benefit supporting the overall well-being and recovery of the patient. It also potentially helps with managing pain and inflammation, common issues faced by many cancer patients. Moreover, the elimination of nausea, another unpleasant side effect of cancer treatments, may significantly improve the patient’s comfort and quality of life. However, it’s important to note that the therapeutic effects of delta-8 THC are still under scientific investigation. Despite the early promising findings, more extensive and rigorous research is required to thoroughly comprehend the full spectrum of effects this cannabinoid can induce. Not only its therapeutic potential needs to be explored further, but the safety of delta-8 THC use also needs to be fully understood. This involves studying the possible adverse effects, interactions with other medications, long-term effects, tolerance, and dependency issues. As such, caution is advised until the scientific community can provide definitive conclusions regarding the effects and safety of delta-8 THC use.

Differences between delta-8 THC and CBD:

• Delta-8 THC is a psychoactive cannabinoid, while CBD is non-intoxicating.
• Delta-8 THC produces a milder and more relaxing high than delta-9 THC, while CBD does not produce a high.
• Delta-8 THC has the potential to produce cognitive distortions such as difficulty concentrating, difficulties with short-term memory, and alerted sense of time, while CBD does not.
• Delta-8 THC is less potent than delta-9 THC, while CBD is more potent.

Safety of delta-8 THC:

Delta-8 THC seems to be safer than delta-9 THC when used responsibly. However, there are still things to watch out for, such as contaminated products and the associated side effects.

Conclusion:

More research is needed to understand the effects and safety of delta-8 THC. However, the available evidence suggests that it may have several potential therapeutic benefits.

According to a study published in the Journal of Cannabis Research, delta-8-THC is a psychoactive substance that is chemically similar to delta-9 THC, the compound often referred to as THC that results in an intoxicating “high.” Delta-8-THC is about half as potent as delta-9 THC and is produced in far less quantity and thus has to be processed from a concentrate ¹². The study also found that most delta-8-THC users experienced a lot or a great deal of relaxation, euphoria, and pain relief. They also experienced cognitive distortions such as difficulty concentrating, difficulties with short-term memory, and alerted sense of time. However, they did not experience anxiety or paranoia ¹. Participants generally compared delta-8-THC favorably with both delta-9-THC and pharmaceutical drugs, with most participants reporting substitution for delta-9-THC and pharmaceutical drugs ¹.

Please note that this is just one study and more research is needed to understand the effects of delta-8-THC on the human body ¹.

Learn more:

1. jcannabisresearch.biomedcentral.com2. buffalo.edu3. forbes.com

How is delta-8 THC different from CBD?

Delta-8 THC and CBD are both cannabinoids found in the cannabis plant, but they have different effects on the human body. Delta-8 THC is a psychoactive compound that is chemically similar to delta-9 THC, the compound that is responsible for the “high” associated with marijuana use. However, delta-8 THC is less potent than delta-9 THC and produces a milder and more relaxing high ¹². Delta-8 THC can also produce cognitive distortions such as difficulty concentrating, difficulties with short-term memory, and alerted sense of time ¹.

CBD, on the other hand, is non-intoxicating and does not produce a “high” ². It has been shown to have potential therapeutic benefits such as reducing anxiety, improving sleep quality, and alleviating pain ². CBD works by interacting with the body’s endocannabinoid system (ECS), which regulates various physiological processes such as mood, appetite, and sleep ².

In summary, while both delta-8 THC and CBD are cannabinoids found in the cannabis plant, they have different effects on the human body. Delta-8 THC produces a milder and more relaxing high than delta-9 THC, while CBD is non-intoxicating and has potential therapeutic benefits ¹².

Learn more:

1. dailymail.co.uk2. cfah.org3. msn.com4. msn.com5. sfweekly.com6. cbdoracle.com— see less

According to a study published in the Journal of Cannabis Research, delta-8 THC is a psychoactive substance that is chemically similar to delta-9 THC, the compound often referred to as THC that results in an intoxicating “high.” Delta-8 THC is about half as potent as delta-9 THC and is produced in far less quantity and thus has to be processed from a concentrate ¹².

Delta-8 THC has been reported to have several potential therapeutic benefits, including relief from pain, nausea, inflammation, loss of appetite, and depression ¹. Delta-8 THC may also stimulate appetite, help with pain and inflammation, and eliminate nausea in cancer patients ². Delta-8 THC may also provide a clearer-headed high compared to ordinary THC and could work topically (applied to the skin) or orally ².

Please note that this is just one study and more research is needed to understand the effects of delta-8 THC on the human body ¹.

Learn more:

1. cfah.org2. healthmj.com3. deltamunchies.com4. health.clevelandclinic.org

According to a Forbes Health article, Delta-8 THC products have not been evaluated or approved for safe use by the FDA and may be marketed in ways that put public health at risk ¹. While delta-8 THC seems to be safer than delta-9 THC when used responsibly, there are still things to watch out for, such as contaminated products and the associated side effects ².

It is important to note that this is just one source of information and more research is needed to understand the safety of delta-8 THC ¹.

Learn more:

1. forbes.com2. cfah.org3. msn.com4. wnky.com5. medicalxpress.com

The scholarly article titled “Marijuana Consumption Is Associated with Lower COVID-19 Severity Among Hospitalized Patients”, authored by Yan and his team of researchers (2023), embarked on a meticulous journey to explore the potential link between present marijuana consumption and the resultant outcomes in patients hospitalized due to COVID-19. This comprehensive study conducted an exhaustive examination into the effects of marijuana on the progression and severity of the virus in these patients. Upon critical assessment, the researchers unearthed some intriguing findings. The study determined that those patients who were active marijuana consumers exhibited lower levels of inflammatory markers upon their admission to the hospital. Inflammatory markers are proteins in the body that increase in response to inflammation, which is a key response of the human body to viral infections such as COVID-19. This reduction in the levels of these markers among active marijuana users suggests a potentially lowered inflammatory response, which could contribute to a less severe progression of the disease. Furthermore, the study indicated that active marijuana users, compared to their non-using counterparts, experienced better clinical outcomes. This included a diminished requirement for admission into intensive care units (ICUs) or the need for mechanical ventilation, which are measures typically indicative of severe disease progression. Thus, the study proposed a potential correlation between active marijuana consumption and a more favorable disease course among hospital-admitted COVID-19 patients. However, Yan et al. (2023) were careful to counsel that their findings should ideally be assessed and understood with caution. The main reason for this suggestion arises from the fact that the study was based on a retrospective analysis. Retrospective analyses involve looking back at collected data from past events and, while they can provide valuable insights, they have inherent limitations. They rely on the accuracy and completeness of past records and are vulnerable to potential recall bias or distortions in the data collected. This could potentially affect the study’s findings and interpretations. Therefore, the authors emphasized the necessity for further research in this field, particularly prospective and observational studies. Prospective studies, which observe subjects forward in time, could provide a clearer understanding of the potential cause-and-effect relationship between marijuana use and COVID-19 severity. Observational studies, which involve watching subjects in a non-controlled environment, can offer additional real-world insights into the effects of marijuana use on those suffering from COVID-19. In conclusion, the pioneering investigation by Yan et al. (2023) highlights a potential association between active marijuana consumption and less severe COVID-19 outcomes among hospitalized patients. However, they underscore the need to approach their findings with caution due to the retrospective nature of their study. The call for further prospective and observational studies underlines the importance of continued research in this area to gain a more thorough understanding of the role of marijuana in COVID-19 patient outcomes.

Key findings

• Active marijuana users had lower levels of inflammatory markers upon admission than non-users.
• Active marijuana users had better clinical outcomes compared to non-users, including lower NIH scores, shorter hospitalization, lower ICU admission rates, and less need for mechanical ventilation.
• After adjusting for covariates, ICU admission was 12 percentage points lower and intubation rates were 6 percentage points lower in marijuana users.

Limitations

• The study was retrospective, which means that the data was collected after the events had occurred. This type of study can identify associations between variables, but it cannot prove that one variable causes the other.
• The study was conducted at a single hospital, so the results may not be generalizable to other populations.
• The study did not collect information on the specific type of marijuana used or the dosage.

Conclusion

The study by Yan et al. (2023) provides some evidence that current marijuana use may be associated with better clinical outcomes in hospitalized patients with COVID-19. However, more research is needed to confirm these findings and to understand the underlying mechanisms.

Sources

info

1. cannabishealthnews.co.uk/2022/05/25/story22-five-new-cannabis-studies-to-have-on-your-radar/

According to a retrospective cohort analysis published in the Journal of Cannabis Research, cannabis consumption is associated with lower COVID-19 severity among hospitalized patients ¹. The study was conducted on 1831 patients admitted to two medical centers in Southern California with a diagnosis of COVID-19. The study found that active cannabis users hospitalized with COVID-19 had better clinical outcomes compared with non-users, including decreased need for ICU admission or mechanical ventilation ¹. However, the results need to be interpreted with caution given the limitations of a retrospective analysis ¹.

It is important to note that this is just one study and more research is needed to understand the relationship between cannabis use and COVID-19 outcomes ¹.

Learn more:

1. jcannabisresearch.biomedcentral.com2. hempgazette.com3. forbes.com4. forbes.com

Heart health is a crucial aspect of overall well-being, and the use of medical marijuana has raised questions about its effects on blood pressure and the heart. While there is still much research to be done to fully comprehend the relationship between medical marijuana and cardiovascular health, it is important to acknowledge that an increased heart rate is a potential side effect of marijuana consumption. This increase in heart rate, although generally harmless, warrants caution when considering the impact of marijuana on heart health.

The method of marijuana consumption plays a significant role in determining its effects on the heart. As a result, when using medical marijuana, it is advisable to consult a knowledgeable medical professional, such as a marijuana doctor, for guidance on the safest and most suitable consumption methods.

Side Effects of Marijuana:

Immediately following the consumption of marijuana, individuals may experience a temporary increase in blood pressure and heart rate, which, in turn, raises the risk of experiencing a stroke or heart attack. Tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, has been linked to inflamed blood pressure and oxidative stress in the artery walls, which can contribute to chronic inflammation and cardiovascular disease. However, it’s essential to note that cannabidiol (CBD), a non-psychoactive compound in marijuana, can counteract the inflammation-inducing effects of THC.

Apart from its potential impact on heart health, THC can also lead to various other side effects. While most of these effects are typically temporary, it’s crucial for marijuana users to remain vigilant. Some of the potential side effects include an accelerated heart rate, anxiety, coordination problems, delayed reaction times, difficulty sleeping, disorientation, dizziness, dry and red eyes, fatigue, hallucinations, headaches, impaired memory, irritability, low blood pressure, mood swings, nausea/vomiting, panic attacks, and paranoia. It’s worth noting that these side effects may be less severe for individuals with higher cannabis tolerances. However, some research suggests that THC might pose long-term risks, particularly impairing thinking, especially in younger users. Individuals are strongly advised not to operate heavy machinery or drive while under the influence of marijuana, and those taking other medications should be aware of potential drug interactions.

Impact on the Heart:

The question often arises: “Is marijuana bad for your heart?” The effects of marijuana on heart health are complex and dependent on factors such as an individual’s current health status, family history of illness, and the method of marijuana ingestion. According to the American Heart Association (AHA), marijuana could have adverse effects on one’s heart and blood vessels. However, more research is needed to comprehensively understand these effects.

Immediately after marijuana use, an individual’s heart rate may temporarily increase, potentially raising the risk of a heart attack or stroke. Research has suggested that young adults who used marijuana between 2007 and 2014 experienced an increased rate of hospitalizations for conditions like cardiac arrest, strokes, and issues related to heart rate and rhythm compared to non-users. Although the evidence supporting these claims is not strong, marijuana use may be associated with a higher risk of atrial fibrillation and ischemic stroke.

A 2019 study published in the Journal of the American College of Cardiology (JACC) found that regular cannabis use could be independently linked to adverse changes in left ventricle size and subclinical dysfunction compared to rare/never cannabis use, but these changes might be reversible upon discontinuation of cannabis use. The method of ingestion also influences the effects of marijuana on the heart; smoking and vaping have been associated with inflammation and an increased risk of clogged arteries, potentially leading to heart attacks and strokes.

Given the potential impact of marijuana on heart health, it is suggested that smoking marijuana could increase the mortality rate among long-term heart attack survivors. However, it is challenging to separate the effects of cannabinoid compounds from the effects of smoking itself. People with a history of heart disease should exercise caution when using marijuana. In summary, it is crucial for all marijuana users to seek guidance from a marijuana doctor to ensure safe consumption practices.

Impact on Blood Pressure:

The effects of cannabinoids on the cardiovascular system can be multifaceted, leading to changes in blood pressure that depend on various factors, including the time since consumption, the individual’s health status, and their frequency of marijuana use.

Immediately after marijuana use, blood pressure may experience a temporary increase, potentially elevating the risk of stroke or heart attack. THC’s inflammatory effects on blood vessels and oxidative stress in the artery walls are linked to higher blood pressure. However, it’s important to recognize the differences between THC and CBD. CBD can counteract THC’s inflammation-inducing tendencies, which means that the THC to CBD ratio can significantly influence marijuana’s impact on blood pressure.

The method of consumption further affects how marijuana influences blood pressure. Smoking and vaping have been associated with inflammation and an increased risk of clogged arteries, which can lead to high blood pressure. Conversely, heavy doses of cannabis can cause a drop in blood pressure, leading to lightheadedness and dizziness.

It’s noteworthy that CBD on its own has demonstrated the potential to reduce resting blood pressure and mitigate stress-induced increases in blood pressure. Additionally, individuals with higher marijuana tolerances are less likely to experience severe side effects, including changes in blood pressure, making them less common among regular users.

Why Does Cannabis Increase Blood Pressure?

Cannabis can indeed elevate blood pressure, primarily due to THC’s potential to cause inflammation in blood vessels and oxidative stress in artery walls. These effects are associated with higher blood pressure, and while further evidence is required to confirm this link, there is a potential increase in the risk of atrial fibrillation immediately after marijuana use. Atrial fibrillation, an irregular heart rhythm, can lead to the formation of blood clots, potentially causing high blood pressure.

Recommendations for Safe Marijuana Use:

Individuals with lung disease, heart health issues, or mental health disorders should carefully consider the potential risks associated with marijuana use. All users should be aware of the potential side effects and begin with a low dosage, preferably under the guidance of a medical marijuana doctor. Overall, while marijuana has demonstrated effects on blood pressure and heart health, more research is necessary to comprehensively understand its impacts. Therefore, seeking advice from a marijuana doctor is essential for using cannabis safely.

FAQ:

1. Does CBD lower blood pressure? While more research is needed, CBD has been shown to have the potential to decrease resting blood pressure and mitigate stress-induced increases in blood pressure.
2. Can weed cause a heart attack? Immediately after smoking marijuana, one’s blood pressure and heart rate may temporarily increase, potentially raising the risk of having a stroke or heart attack.
3. Is weed bad for the heart? The American Heart Association (AHA) suggests that marijuana could negatively impact one’s heart and blood vessels, but further research is required to fully understand these effects.
4. Does weed increase heart rate? Increased heart rate is a possible side effect of marijuana, especially immediately after smoking.

Speaking of blood pressure, you might be interested in blood pressure and its significance in maintaining overall heart health. Additionally, understanding the impact of medical marijuana on the cardiovascular system is crucial. To delve deeper into the topic, you might find it informative to explore medical cannabis and its effects on heart rate and blood vessels. Furthermore, it is worth considering the potential risks associated with smoking and vaping marijuana, such as inflammation and increased risk of clogged arteries. For more information on the subject, you can refer to the article on

The Journal of Pain https://www.jpain.org/  publishes original articles, reviews, and focus articles related to all aspects of pain, including basic, translational, and clinical research, epidemiology, education, and health policy. The journal is the scientific publication of the United States Association for the Study of Pain (USASP), whose mission is to promote scientific advances that reduce the burden of pain.

The study is one of the most recent and rigorous studies to investigate the effectiveness of medical cannabis for chronic pain. The study was published in the journal Pain, which is a leading journal in the field of pain research.

The study involved 114 adults with chronic pain who were given either medical cannabis or a placebo for 4 weeks. The participants were randomized to receive either medical cannabis or placebo, meaning that the assignment was random and neither the participants nor the researchers knew which group they were in until the end of the study.

The medical cannabis used in the study was a whole-plant extract that contained both THC and CBD. The THC was the main psychoactive compound in the extract, and the CBD was a non-psychoactive compound that is known for its anti-inflammatory and pain-relieving effects.

The results of the study showed that the adults who received medical cannabis had a significant reduction in their pain levels, compared to the adults who received the placebo. The reduction in pain was greatest in the participants who had neuropathic pain, which is a type of pain caused by nerve damage.

The study also found that medical cannabis was well-tolerated by the participants. The most common side effects were mild and included dry mouth, dizziness, and fatigue.

Overall, the findings of this study suggest that medical cannabis is a safe and effective treatment for chronic pain, especially neuropathic pain. More research is needed to confirm these findings and to better understand the long-term safety and efficacy of medical cannabis for chronic pain.

Here are some additional insights into the study:

• The participants in the study had a variety of chronic pain conditions, including back pain, neck pain, arthritis, and neuropathic pain.
• The participants were given a standardized dose of medical cannabis. The dose was adjusted as needed based on the participant’s response to treatment.
• The participants were assessed for pain levels, quality of life, and adverse events at baseline and at the end of the study.

The researchers concluded that “medical cannabis is a safe and effective treatment for chronic pain, especially neuropathic pain.” They also stated that “more research is needed to confirm these findings and to better understand the long-term safety and efficacy of medical cannabis for chronic pain.”

The findings of this study are encouraging for people with chronic pain who are seeking alternative treatment options. Medical cannabis may be a viable option for people who have not found relief from other treatments or who are experiencing side effects from other medications.

The FDA’s approval of the first clinical trial of medical cannabis for autism is a significant milestone, as it represents the first time that the FDA has recognized the potential of medical cannabis to treat a neurodevelopmental disorder.

The trial will be conducted by researchers at the University of California, Davis, and will involve 120 children with autism spectrum disorder (ASD) who are between the ages of 6 and 17. Participants will be randomly assigned to receive either a medical cannabis extract or a placebo for 12 weeks. The researchers will assess the participants’ symptoms of anxiety, hyperactivity, and irritability before and after treatment to determine the efficacy of medical cannabis.

The trial is expected to begin in early 2024 and is expected to last for two years. The results of the trial could have a major impact on the treatment of ASD, as they could provide the first scientific evidence that medical cannabis is safe and effective for treating the symptoms of this disorder.

In addition to the trial at UC Davis, there are a number of other clinical trials of medical cannabis for ASD underway around the world. For example, a trial in Israel is investigating the use of medical cannabis to treat the core symptoms of ASD, such as social communication and repetitive behaviors. Another trial in Australia is investigating the use of medical cannabis to treat anxiety and sleep problems in children with ASD.

The growing body of research on medical cannabis for ASD is promising, and the FDA’s approval of the first clinical trial in the US is a major step forward. The results of these trials could lead to new and effective treatment options for children and adults with ASD.

Here are some additional details about the UC Davis clinical trial:

• The trial will be funded by the National Institutes of Health (NIH).
• The medical cannabis extract that will be used in the trial is a whole-plant extract that contains both THC and CBD.
• The researchers will carefully monitor the participants for any adverse events.
• The results of the trial will be published in a peer-reviewed journal.

The outcome of this and other clinical trials will be eagerly awaited by families of children with ASD and by the medical community as a whole.

The researchers will assess the participants’ symptoms of anxiety, hyperactivity, and irritability before and after treatment to determine the efficacy of medical cannabis ¹.

The trial is expected to begin in early 2024 and is expected to last for two years. The results of the trial could have a major impact on the treatment of ASD, as they could provide the first scientific evidence that medical cannabis is safe and effective for treating the symptoms of this disorder ¹.

In addition to the trial at UC Davis, there are a number of other clinical trials of medical cannabis for ASD underway around the world. For example, a trial in Israel is investigating the use of medical cannabis to treat the core symptoms of ASD, such as social communication and repetitive behaviors. Another trial in Australia is investigating the use of medical cannabis to treat anxiety and sleep problems in children with ASD ¹.

The growing body of research on medical cannabis for ASD is promising, and the FDA’s approval of the first clinical trial in the US is a major step forward. The results of these trials could lead to new and effective treatment options for children and adults with ASD.

Learn more:

1. molecularautism.biomedcentral.com2. cannamd.com3. n.neurology.org4. spectrumnews.org5. health.ucsd.edu6. 7news.com.au7. thinkingautism.org.uk8. jcannabisresearch.biomedcentral.com9. thinkingautism.org.uk10. hightimes.com11. clinicaltrials.ucsd.edu12. clinicaltrials.gov

Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients

Authors: Rayyan Zafar, Anne Schlag, Lawrence Phillips, David J Nutt

Journal: BMJ Paediatrics Open

Publication Date: October 31, 2023

Abstract

This study investigated the feasibility of using whole-plant cannabis medicines to treat seizures in children with severe treatment resistant epilepsy. Ten children were recruited from two charities and treated with a range of whole-plant medical cannabis oils. Seizure frequency reduced by 86% across all 10 participants, with no significant adverse events. Participants also reduced their use of antiepileptic drugs from an average of seven to one following treatment with medical cannabis. The study authors concluded that whole-plant medical cannabis is a feasible, effective, and well-tolerated treatment for reducing seizure frequency in children with severe treatment resistant epilepsy.

Discussion

This study provides further evidence of the potential benefits of medical cannabis for children with severe treatment resistant epilepsy. The findings are particularly significant given that the study participants had all failed on multiple traditional antiepileptic drugs and many had also failed on the licensed CBD preparation Epidyolex.

The study authors note that their findings justify the potential value of further research into the reported therapeutic benefit of whole-plant medicinal cannabis products. This is especially important given that medical cannabis is currently only available to a very small number of children in the UK through private prescriptions.

The results of this study are also encouraging for families of children with severe treatment resistant epilepsy, who may be looking for alternative treatment options. However, it is important to note that this study was a case-series, which is a type of observational study that cannot definitively prove that medical cannabis is effective for this condition. More rigorous research, such as randomized controlled trials, is needed to confirm the findings of this study and to better understand the long-term safety and efficacy of medical cannabis for children with severe treatment resistant epilepsy.

Sources

info

1. www.ncbi.nlm.nih.gov/pmc/articles/PMC8689159/

This study published in the BMJ Paediatrics Open journal on October 31, 2023, investigated the feasibility of using whole-plant cannabis medicines to treat seizures in children with severe treatment-resistant epilepsy. The study recruited ten children from two charities and treated them with a range of whole-plant medical cannabis oils. The study found that seizure frequency reduced by 86% across all 10 participants, with no significant adverse events. Participants also reduced their use of antiepileptic drugs from an average of seven to one following treatment with medical cannabis. The study authors concluded that whole-plant medical cannabis is a feasible, effective, and well-tolerated treatment for reducing seizure frequency in children with severe treatment-resistant epilepsy¹.

The study authors note that their findings justify the potential value of further research into the reported therapeutic benefit of whole-plant medicinal cannabis products. This is especially important given that medical cannabis is currently only available to a very small number of children in the UK through private prescriptions¹.

It is important to note that this study was a case-series, which is a type of observational study that cannot definitively prove that medical cannabis is effective for this condition. However, the results are encouraging for families of children with severe treatment-resistant epilepsy who may be looking for alternative treatment options¹.

Learn more:

1. bmjpaedsopen.bmj.com2. leafwell.com3. frontiersin.org4. epilepsy.org.uk5. bmjpaedsopen.bmj.com6. orcid.org7. creativecommons.org— see less

Explore

Medical cannabis contains hundreds of natural chemicals, including cannabidiol (CBD) and tetrahydrocannabinol (THC). CBD does not have the mood-altering effects often associated with cannabis. THC is the part of the cannabis plant that makes people feel ‘high’. Research has shown that CBD, a chemical component of marijuana, may help control seizures in patients with epilepsy. Cannabinoids can also help in treating epilepsy by binding to specific brain receptors called CB1 and CB2. These receptors, in turn, slow down the release of neurotransmitters such as glutamate that stimulate the central nervous system and may result in seizures ¹²³⁴.

The study published in the BMJ Paediatrics Open journal on October 31, 2023, investigated the feasibility of using whole-plant cannabis medicines to treat seizures in children with severe treatment-resistant epilepsy. The study found that seizure frequency reduced by 86% across all 10 participants, with no significant adverse events. Participants also reduced their use of antiepileptic drugs from an average of seven to one following treatment with medical cannabis. The study authors concluded that whole-plant medical cannabis is a feasible, effective, and well-tolerated treatment for reducing seizure frequency in children with severe treatment-resistant epilepsy ¹.

The study authors note that their findings justify the potential value of further research into the reported therapeutic benefit of whole-plant medicinal cannabis products. This is especially important given that medical cannabis is currently only available to a very small number of children in the UK through private prescriptions ¹.

It is important to note that this study was a case-series, which is a type of observational study that cannot definitively prove that medical cannabis is effective for this condition. However, the results are encouraging for families of children with severe treatment-resistant epilepsy who may be looking for alternative treatment options ¹.

Learn more:

1. epilepsy.org.uk2. mymmjdoctor.com3. choumd.com4. healthnews.com5. theherbalclinicmd.com6. epilepsy.com7. epilepsy.org.au8. nhs.uk9. gettyimages.com

Cannabis terpenes are compounds that give cannabis its distinctive aroma and flavor. They are also believed to influence the psychoactive and medicinal properties of cannabis. However, a new study suggests that the importance of terpenes in determining the aroma of cannabis may be overstated.Researchers from Abstrax Tech, a U.S. company focused on aromatic compounds from cannabis and other plants, analyzed 31 cannabis ice hash rosin extracts, a potent cannabis product made by combining ice water and rosin pressing. They used advanced techniques to identify various compounds that create the distinct aromas of cannabis.Their findings revealed that numerous minor non-terpenoid compounds are closely associated with atypical sweet or savory scents produced by cannabis. In particular, the authors identified a novel class of volatile sulfur compounds responsible for the unique aromas of cannabis, which complement and enhance the terpenes’ aromatic effects.For example, researchers found that the skunky and woody aroma of the cannabis strain Dogwalker OG is not solely due to its dominant terpenes, limonene and caryophyllene. Rather, it is also due to the presence of novel sulfur compounds.Similarly, the citrus and tropical scent of the strain Tropicana Cookies is not solely due to its dominant terpenes, limonene and myrcene. It is also due to the presence of novel sulfur compounds.Even the sweet grape-like aroma of the strain Purple Punch is not solely due to its dominant terpene, myrcene. It is also due to the presence of novel sulfur compounds.These findings suggest that the conventional belief that dominant terpenes solely determine the aromatic characteristics of cannabis strains is not accurate.The study’s authors also found that strains with significantly different aroma profiles are often grouped together when classified by their dominant terpenes. For example, Dogwalker OG, Tropicana Cookies, and Purple Punch were all grouped in the same limonene/caryophyllene cluster, despite their distinct aromas.This suggests that while terpene profiles may be helpful for chemotaxonomic purposes (i.e., classifying cannabis strains based on their chemical composition), they may not be as accurate for differentiating strains based on their aroma profiles.The study’s authors conclude that “the importance of terpenes appears to be overstated.” They suggest that more research is needed to better understand the role of sulfur compounds and other non-terpenoid compounds in the aroma of cannabis.

Implications of the study:

The findings of this study have several implications for the cannabis industry and for consumers.

For the cannabis industry, the study suggests that terpenes may not be a reliable way to differentiate cannabis strains based on their aroma profiles. This could lead to more accurate and informative labeling of cannabis products.

For consumers, the study suggests that they should not rely solely on terpene profiles when choosing cannabis products. Instead, they should consider other factors, such as the strain’s name, reputation, and the desired aroma profile.

Overall, this study provides new insights into the chemistry of cannabis aroma and challenges the conventional belief that terpenes are the sole determinants of a strain’s aroma profile. More research is needed to better understand the role of sulfur compounds and other non-terpenoid compounds in the aroma of cannabis.

Abstrax Tech, a U.S. company focused on aromatic compounds from cannabis and other plants, analyzed 31 cannabis ice hash rosin extracts to identify various compounds that create the distinct aromas of cannabis ¹. Their findings revealed that numerous minor non-terpenoid compounds are closely associated with atypical sweet or savory scents produced by cannabis. In particular, the authors identified a novel class of volatile sulfur compounds responsible for the unique aromas of cannabis, which complement and enhance the terpenes’ aromatic effects ¹.

The study suggests that the conventional belief that dominant terpenes solely determine the aromatic characteristics of cannabis strains is not accurate ¹. For example, researchers found that the skunky and woody aroma of the cannabis strain Dogwalker OG is not solely due to its dominant terpenes, limonene and caryophyllene. Rather, it is also due to the presence of novel sulfur compounds ¹. Similarly, the citrus and tropical scent of the strain Tropicana Cookies is not solely due to its dominant terpenes, limonene and myrcene. It is also due to the presence of novel sulfur compounds ¹. Even the sweet grape-like aroma of the strain Purple Punch is not solely due to its dominant terpene, myrcene. It is also due to the presence of novel sulfur compounds ¹.

The study’s authors also found that strains with significantly different aroma profiles are often grouped together when classified by their dominant terpenes ¹. For example, Dogwalker OG, Tropicana Cookies, and Purple Punch were all grouped together despite having significantly different aroma profiles ¹.

Learn more:

1. forbes.com2. healthline.com3. weedmaps.com4. leafly.com5. cnbsjournal.com6. bing.com7. abstraxtech.com8. abstraxtech.com9. leafly.com

The latest data from the United Kingdom unveils a significant upsurge in the importation of medical cannabis over the past twelve months, indicating a growing trend and highlighting increased acceptance and utilization in the medical community. More specifically, the sheer volume of imported medical cannabis has tripled within the span of a single year, marking a drastic rise in the UK’s dependency on the medicinal plant. The figures have dramatically soared from 7,762 kilograms in 2022 to a whopping 23,890 kilograms in 2023, representing a nearly three-fold increase in the quantity of medical cannabis brought into the country. This steep upward trajectory in medical cannabis imports into the UK underscores a broader shift towards acknowledging the significant role of this plant in the realm of medicine and in patients’ lives. Medical cannabis is known to have a plethora of therapeutic benefits including pain relief, reducing anxiety, and managing the symptoms of several chronic diseases, which probably explains the growing demand for it. Moreover, the report reveals another significant statistic, that is, the exponential increase in the number of cannabis medications reported for import. From March to October of the current year, the number exploded from just 3,741 to an astounding 37,543, marking a 900% surge. This dramatic rise during a relatively short period suggests not only an acceptance of medical cannabis but also a robust infrastructure capable of handling such high volumes of import. Furthermore, the estimated number of private patients receiving cannabis prescriptions in the UK has been revealed to be between 1,500 and 2,500. This figure is indicative of the growing number of patients using cannabis-based medication, creating a new wave of demand within the medical landscape. The inclusion of cannabis in their treatment plans signifies its potential role in enhancing the quality of life for those struggling with various health conditions. All in all, the data paints a clear picture of a rising demand for medical cannabis in the UK. The tripled import figures, the 900% increase in cannabis medications reported for import, and the rising number of private patients receiving cannabis prescriptions all point toward the same conclusion: the usage of medical cannabis is on an upward trajectory in the UK. This marked increase in demand and acceptance of medical cannabis heralds a new era in the medical community, as traditional medicine starts embracing more natural and alternative forms of treatment. The implications of this trend are significant and far-reaching, heralding a potential shift in public health policy and the therapeutic landscape of the country.

Implications:

The tripling of medical cannabis imports in the UK over the past year is a significant development, suggesting a growing demand for this treatment option. This increase in demand is likely being driven by a number of factors, including:

• Greater awareness of the potential benefits of medical cannabis among patients and healthcare professionals
• Increased availability of medical cannabis products through private clinics
• More research supporting the use of medical cannabis for a variety of conditions

Despite the increase in demand, the UK medical cannabis market is still relatively small, and the supply of products is still predominantly reliant on imports. However, a number of domestic cultivation enterprises have begun to produce medical cannabis locally, which could help to reduce reliance on imports and improve the quality and consistency of products.

Conclusion:

The increasing demand for medical cannabis in the UK is a positive development for patients who may benefit from this treatment option. The UK government should continue to support the development of the domestic medical cannabis industry, in order to improve access to high-quality products for patients.

Further insights:

The following links provide further insights into the UK medical cannabis industry:

• UK medical cannabis imports have tripled in size this year: https://pressat.co.uk/releases/uk-medical-cannabis-imports-have-tripled-in-size-this-year-1d53a78aebc362d4dd2d4b2abdfa32f9/
• Huge Rise In UK Medical Cannabis Imports As Private Sector Steps-Up To Meet Patient Demand: https://www.cannabisbusinessexecutive.com/2021/01/huge-rise-uk-medical-cannabis-imports-private-sector-steps-meet-patient-demand/

/.

You might be interested in exploring the topic of medical cannabis further. Speaking of medical cannabis, you might find the following Wikipedia articles informative: Medical cannabis provides an overview of the medicinal uses and legalization of cannabis. Cannabis in the United Kingdom offers specific insights into the regulations and history of cannabis in the UK. These articles can provide you with additional information on the subject.

The Economic Times Health¹ has recently shed light on a fascinating trend that is steadily gaining traction in India’s healthcare sector: the burgeoning adoption of cannabis medicine. This upward trend is largely credited to the perceived therapeutic advantages that cannabis offers for handling a wide array of health conditions such as chronic pain, epileptic disorders, and anxiety-related issues. Cannabis-based medical applications showcase tremendous potential, however, the issue of regulatory control continues to be a complex puzzle for the Indian government to solve. In a proactive move to tap into the immense potential that medicinal cannabis presents, the Indian government took a significant stride in 2020 by granting authorization for the cultivation of cannabis. This decision was made with the intention of promoting research and development within the rapidly evolving sector of cannabis-derived medicine¹. The green light for cannabis cultivation not only indicates a shift in governmental attitudes towards the plant but also opens up new avenues for exploring its medicinal benefits. Interestingly, there is a steeply rising demand for treatments derived from cannabis within the Indian population. This is largely fueled by patients who are vigorously seeking out alternative therapeutic options for their existing health conditions. A significant portion of these individuals has been disillusioned by the side effects and inefficacy of traditional medications, and see in cannabis a potential lifeline. This shift towards cannabis-based treatments indeed represents a new wave in India’s healthcare scene. Yet, this burgeoning trend is not without its share of challenges. One of the most formidable obstacles that obstruct the path to widespread adoption of cannabis-based medicine is the alarming lack of awareness and comprehensive understanding about these treatments. Both healthcare practitioners and patients exhibit a significant deficiency in their knowledge about these medicines¹. This gap in knowledge often leads to misconceptions, unfounded fears, and hesitation about the use of cannabis as a legitimate form of medical treatment. To address these issues, the article emphasizes strongly on the necessity for thorough and nuanced research on medicines that are based on cannabis. Such research could potentially illuminate the various ways in which cannabis could be utilized for therapeutic purposes. Concurrently, it could also reveal any potential risks and side effects that may be associated with the usage of cannabis-based treatments¹. Moreover, the article urgently calls for increased educational efforts targeted towards both healthcare professionals and patients. These efforts should aim to dispel myths, reduce stigma, and build a robust understanding of the potential benefits and risks that cannabis-based treatments may carry. This will enable healthcare practitioners to make informed decisions about incorporating these treatments into their practice, and empower patients to make educated choices about their health¹. In conclusion, the report by Economic Times Health¹ puts forth a compelling argument for the need to push forward with research and educational initiatives related to cannabis-based medicine in India. While the adoption of cannabis as a legitimate form of medical treatment is still in its infancy in the country, the potential benefits it offers cannot be denied. With a balanced approach that includes rigorous research and targeted education, India could potentially unlock a new era in its healthcare sector.

¹: Economic Times Health

Read more at:
https://health.economictimes.indiatimes.com/news/industry/catapulting-indias-medical-wisdom-the-surge-of-cannabis-medicine/104835238

According to a recent article on Economic Times Health, India is experiencing a surge in the use of cannabis medicine¹. The article highlights the potential benefits of cannabis in treating various medical conditions such as chronic pain, epilepsy, and anxiety. It also discusses the challenges faced by the Indian government in regulating the use of cannabis for medicinal purposes.

The article mentions that the Indian government has been taking steps to legalize cannabis for medical use. In 2020, the government approved the cultivation of cannabis for medical and industrial purposes. This move was aimed at promoting research and development in the field of cannabis-based medicines¹.

The article also notes that there is a growing demand for cannabis-based medicines in India. This demand is being driven by an increasing number of patients who are seeking alternative treatments for their medical conditions. However, the lack of awareness and education about cannabis-based medicines among healthcare professionals and patients remains a major challenge¹.

In conclusion, the article suggests that there is a need for more research and development in the field of cannabis-based medicines in India. It also emphasizes the importance of educating healthcare professionals and patients about the potential benefits and risks associated with these medicines¹.

¹: Economic Times Health

Learn more:

1. health.economictimes.indiatimes.com2. economictimes.indiatimes.com3. economictimes.indiatimes.com4. health.economictimes.indiatimes.com

Here are some websites that offer medical cannabis products in India:

1. ItsHemp: ItsHemp offers a wide range of cannabis-based products, including CBD oil, hemp, and medical cannabis. They have over 2000+ products and ship all over India.
2. CBD Store: CBD Store offers premium medical cannabis and CBD products. They curate ancient remedies and medicines of the mind, body, and soul.
3. Hempstreet: Hempstreet is India’s first research-to-retail venture in the Ayurvedic cannabis solution. They offer the best medical consultation and treatment with certified medical practitioners across the country.

Learn more:

1. itshemp.in2. cbdstore.in3. themarijuanaconsumer.com4. hempstreet.in